Dysbiosis of gut microbiota and decreased propionic acid associated with metabolic abnormality in Cushing’s syndrome

Objective Chronic hypercortisolism leads to a phenotype resembling metabolic syndrome. We aimed to investigate the association between gut microbiota and metabolic abnormalities in endogenous hypercortisolism (Cushing’s syndrome). Methods A total of 23 patients with Cushing’s syndrome (18 female and 5 men, aged 47.24 ± 12.99 years) and 30 age-, sex-and BMI-matched healthy controls (18 female and 12 men, aged 45.03 ± 6.69 years) were consecutively recruited. Differences in gut microbiota and plasma short-chain fatty acid (SCFAs) concentrations between the Cushing’s syndrome patients and controls were analyzed by 16S rRNA sequencing and gas chromatography-mass spectrometry (GC-MS). Results Compared to the controls, the Simpson and Pielou indices of α diversity were dramatically decreased in Cushing’s syndrome (P < 0.05). The gut microbiota community structure differed significantly between Cushing’s syndrome patients and controls. Compared to controls, the bacterial communities of the Cushing’s syndrome patients were enriched in Proteobacteria and Escherichia-Shigella, and depleted in Firmicutes, including Agathobacter, Blautia, Anaerostipes, Eubacterium_eligens_group, and Lachnospira. Spearman analysis demonstrated that HbA1c, SBP, DBP, and cortisol levels were significantly positively correlated with Proteobacteria and Escherichia-Shigella, whereas negatively correlated with Agathobacter, Blautia, Anaerostipes, Eubacterium_hallii_group, and Lachnospira, etc. Cushing’s syndrome patients also had a lower propionic acid concentration (0.151±0.054 vs. 0.205±0.032 µg/mL, P=0.039) than controls. Furthermore, the level of propionic acid was negatively correlated with systolic pressure and cortisol levels (P<0.05). Conclusion Gut microbiota dysbiosis and decreased propionic acid levels were observed in patients with Cushing’s, suggesting that the gut microbiota may be a potential therapeutic intervention target to improve hypercortisolism-related metabolic abnormalities.

[1]  K. Mizuguchi,et al.  Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota , 2022, Nature Communications.

[2]  Xiangming Mao,et al.  Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis , 2022, Microbiome.

[3]  X. Mao,et al.  Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis , 2022, Microbiome.

[4]  R. Landberg,et al.  The Effects of High Fiber Rye, Compared to Refined Wheat, on Gut Microbiota Composition, Plasma Short Chain Fatty Acids, and Implications for Weight Loss and Metabolic Risk Factors (the RyeWeight Study) , 2022, Nutrients.

[5]  H. Law,et al.  Integrative Analysis of Gut Microbiota and Fecal Metabolites in Rats after Prednisone Treatment , 2021, Microbiology spectrum.

[6]  P. Chanson,et al.  Consensus on diagnosis and management of Cushing's disease: a guideline update. , 2021, The lancet. Diabetes & endocrinology.

[7]  Xu-zhi Wan,et al.  Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice , 2021, Microbiome.

[8]  J. Speakman,et al.  The gut microbiota and its products: Establishing causal relationships with obesity related outcomes , 2021, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[9]  J. Schertzer,et al.  Metabolic endotoxemia is dictated by the type of lipopolysaccharide. , 2021, Cell reports.

[10]  F. Bäckhed,et al.  Conversion of dietary inositol into propionate and acetate by commensal Anaerostipes associates with host health , 2021, Nature Communications.

[11]  R. Gold,et al.  Propionic Acid Rescues High-Fat Diet Enhanced Immunopathology in Autoimmunity via Effects on Th17 Responses , 2021, Frontiers in Immunology.

[12]  M. Arumugam,et al.  Trans-ethnic gut microbial signatures of prediabetic subjects from India and Denmark , 2021, Genome Medicine.

[13]  N. Aljohani,et al.  Gut Hormones in Health and Obesity: The Upcoming Role of Short Chain Fatty Acids , 2021, Nutrients.

[14]  D. Annane,et al.  Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. , 2020, The Journal of clinical investigation.

[15]  O. Pedersen,et al.  Gut microbiota in human metabolic health and disease , 2020, Nature Reviews Microbiology.

[16]  P. Cotter,et al.  Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health , 2020, Gut microbes.

[17]  C. Rotimi,et al.  Gut Microbiome Profiles Are Associated With Type 2 Diabetes in Urban Africans , 2020, Frontiers in Cellular and Infection Microbiology.

[18]  A. Tabarin,et al.  Cushing's syndrome: Treatment and new therapeutic approaches. , 2020, Best practice & research. Clinical endocrinology & metabolism.

[19]  R. Cox,et al.  Monitoring type 2 diabetes from volatile faecal metabolome in Cushing’s syndrome and single Afmid mouse models via a longitudinal study , 2019, Scientific Reports.

[20]  Jing Li,et al.  Glucorticoid-induced obesity individuals have distinct signatures of the gut microbiome. , 2019, BioFactors.

[21]  Jingyuan Fu,et al.  Structural variation in the gut microbiome associates with host health , 2019, Nature.

[22]  W. D. de Vos,et al.  Reclassification of Eubacterium hallii as Anaerobutyricum hallii gen. nov., comb. nov., and description of Anaerobutyricum soehngenii sp. nov., a butyrate and propionate-producing bacterium from infant faeces. , 2018, International journal of systematic and evolutionary microbiology.

[23]  C. Hoffmann,et al.  The human gut microbiota: Metabolism and perspective in obesity , 2018, Gut microbes.

[24]  M. Korbonits,et al.  Metabolic Syndrome in Cushing's Syndrome Patients. , 2018, Frontiers of hormone research.

[25]  Xia Li,et al.  11&bgr;‐Hydroxysteroid Dehydrogenase Type 1 in Obese Subjects With Type 2 Diabetes Mellitus , 2017, The American journal of the medical sciences.

[26]  E. Denamur,et al.  Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli , 2017, Transplantation.

[27]  W. D. de Vos,et al.  Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice , 2016, npj Biofilms and Microbiomes.

[28]  Niki Karavitaki,et al.  Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. , 2016, The lancet. Diabetes & endocrinology.

[29]  N. Boutagy,et al.  Metabolic endotoxemia with obesity: Is it real and is it relevant? , 2016, Biochimie.

[30]  Na-Ri Shin,et al.  Proteobacteria: microbial signature of dysbiosis in gut microbiota. , 2015, Trends in biotechnology.

[31]  K. Strissel,et al.  Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice , 2014, The ISME Journal.

[32]  Jimmy D Bell,et al.  Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults , 2014, Gut.

[33]  Liping Zhao,et al.  An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice , 2012, The ISME Journal.

[34]  Hua V. Lin,et al.  Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms , 2012, PloS one.

[35]  M. Dijkstra,et al.  Regulation of adipokine production in human adipose tissue by propionic acid , 2010, European journal of clinical investigation.